June 2026 Issue No.6 | Highlights of Bio-manufacturing Industry News

30-Second Hot Topic Snapshot

General Secretary Publishes Article in Qiushi, Identifying Biomanufacturing as the Primary Focus for Future Industries

First Special Policy for Marine Biomedicine Released, Aiming for Industry Scale to Exceed 130 Billion

STAR Market Issues New Rules, Explicitly Supporting the Listing of Hard-Tech Enterprises in Biomanufacturing

Bacteria “Train” NK Cells to Initiate Long-Term Immune Protection Against Cancer Metastasis

China's First RNA-Based Biopesticide Officially Approved, Entering Commercialization Phase

$10.5 Billion! Innovent and Pfizer Reach Global Strategic Partnership

Shenzhen Pufei Bio Completes New Round of Financing Close to RMB 100 Million

DPBIO Completes Over RMB 120 Million in Series B+ Financing

The construction of the National Innovation Center is accelerating, with 18 companies already signed on.

On June 1, the 11th issue of Qiushi Journal published an important article by General Secretary Xi Jinping entitled “Forward-Looking Layout and Development of Future Industries.” The article explicitly identifies biomanufacturing and quantum technology as core focal areas for future industries, emphasizes the principle of “industry posing questions, science and technology providing answers,” and supports central state-owned enterprises in developing future industries in alignment with their primary responsibilities and core businesses, so as to cultivate leading scientific and technological enterprises and unicorn companies.

Image source: Qiushi Network

On June 17, the Shanghai Stock Exchange (SSE) released a draft for public consultation on new regulations for the STAR Market, expanding its scope to include fields such as biological products, genetically engineered drugs and vaccines, and biomedical engineering. On the same day, Wu Qing, Chairman of the China Securities Regulatory Commission (CSRC), explicitly stated at the Lujiazui Forum that support would be extended to the listing of “hard technology” enterprises in sectors such as biomanufacturing, quantum technology, and embodied AI on the STAR Market.

On May 28, eight departments, including the Ministry of Natural Resources, jointly issued the "Guiding Opinions on Accelerating the High-Quality Development of Marine Drugs and Functional Products," proposing for the first time a full-chain innovation model integrating the "resource chain, technology chain, industry chain, and application chain." The value-added output of the marine biomedical industry is projected to exceed RMB 130 billion by 2030. The supply of raw materials for marine biomanufacturing and the development of deep-sea biological genetic resources have been incorporated into key strategic layouts.

Cell, June 12. The team led by Lei Xiaoguang from Peking University, in collaboration with the team led by Yan Jianbin from the Shenzhen Institute of Synthetic Biology, Chinese Academy of Agricultural Sciences, has for the first time fully elucidated the de novo biosynthetic pathways of two key anticancer alkaloids (cephalotaxine and homoharringtonine) in Cephalotaxus fortunei, and successfully achieved their heterologous reconstruction in tobacco. (See this issue’s Industry Monthly Report for details.)

Schematic Diagram of the Biosynthetic Pathways of Cephalotaxine and Homoharringtonine

Molecular Therapy, June 3. The Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, in collaboration with the University of Hong Kong, has for the first time revealed that therapeutic attenuated Salmonella can “train” natural killer (NK) cells to establish “trained immunity,” providing sustained anti-metastatic protection for 3 to 4 months even after the bacteria are completely cleared. This discovery extends the concept of “trained immunity” from infectious immunity to the field of tumor metastasis prevention and treatment. (See this issue’s Industry Monthly Report for details.)

Schematic Diagram of the Mechanism by Which Bacteria “Train” NK Cells to Form Immunological Memory

On May 27, "Fusarium compactum Protein MM-135," independently developed by Momi Biotech, was approved as a novel food ingredient. The product had previously obtained U.S. FDA GRAS certification, making it one of the few mycoprotein products to gain market access in both China and the United States, marking the entry of Chinese players into the alternative protein sector.

On May 29, Innovent and Pfizer entered into a global strategic collaboration encompassing licensing, co-development, and commercialization of 12 innovative oncology projects, with total deal value reaching up to $10.5 billion. Innovent received a $650 million upfront payment plus up to $9.85 billion in milestone payments. The collaboration covers multiple novel ADC and multispecific antibody programs.

On June 14, China’s first RNA-based biopesticide, “Tobacco Mosaic Virus Capsid Protein Nucleic Acid Interferon,” was officially certified and launched. It achieves an inhibition rate of over 85% against target viruses, with its active ingredients fully degrading within three to four days. The transition from regulatory approval in May to commercialization in June demonstrates remarkable speed. In addition to tobacco, it can be widely applied to various solanaceous crops, including tomatoes and peppers.